Methyl 6,8-dideoxy-6-(1-methyl-4-propyl-2-pyrrolidinecarboxamido)-1-thio-D-erythro-α-D-galactooctopyranoside hydrochloride monohydrate — CAS 7179-49-9 — represents the monohydrated hydrochloride salt of the parent lincosamide antibiotic lincomycin. The molecule integrates a methyl 1-thio-α-D-galactooctopyranoside core in which positions 6 and 8 have been deoxygenated, with the 6-amino group acylated by trans-1-methyl-4-propyl-L-pyrrolidine-2-carboxylic acid. In solid-state characterisation, the monohydrate crystallises as a colourless to white, hygroscopic powder that exhibits a specific optical rotation of approximately +137° to +145° (c = 1, water, calculated on the anhydrous basis) when tested per Ph. Eur. 2.2.7 and USP 〈781〉. The water content, determined by Karl Fischer coulometric titration at 25°C under nitrogen blanket, lies in the range 4.5–5.5% w/w, a value that must be strictly maintained during storage at 15–25°C in tight containers to prevent dissociation of the lattice-bound water and subsequent hydrolytic degradation of the thioether linkage.
What Differentiates Lincomycin Hydrochloride Monohydrate from the Anhydrous Salt and from Semi-Synthetic Clindamycin?
The monohydrate form differs critically from the anhydrous hydrochloride in processing behaviour during wet granulation and direct compression. When anhydrous lincomycin HCl is exposed to ambient relative humidity exceeding 60% during roller compaction on a 20 kN Alexanderwerk WP 120 Pharma, rapid water uptake can induce unpredictable 1.5–2.0% weight gain within 30 min, leading to punch sticking and weight variability outside the ±5% acceptance range per Ph. Eur. 2.9.5. By contrast, the pre-formed monohydrate exhibits stable water activity (aw 0.35) and reduced hygroscopicity, making it the preferred form for dry blend formulations. With respect to clindamycin hydrochloride (CAS 21462-39-5), the structural distinction is the single stereoselective replacement of the 7(R)-hydroxyl group in lincomycin with a 7(S)-chlorine atom, achieved by chlorination with triphenylphosphine and carbon tetrachloride. This substitution increases potency 4- to 8-fold against susceptible Gram-positive cocci and substantially improves oral bioavailability, but also narrows the safety margin with respect to Clostridioides difficile colitis. A comparative overview of pharmacopoeial specifications is provided in the table below.
| Parameter | Lincomycin HCl Monohydrate (USP/Ph. Eur.) | Clindamycin HCl (USP/Ph. Eur.) |
|---|---|---|
| Assay (anhydrous, solvent-free basis) | 95.0–105.0% (HPLC, 210 nm) | 94.0–102.0% (HPLC, 210 nm) |
| Specific optical rotation | +137° to +145° (c=1, water) | +135° to +150° (c=1, water) |
| Water content (monohydrate) | 4.5–5.5% (KF) | 3.0–6.0% (if monohydrate form) |
| Residual solvents — Class 2 (ICH Q3C) | Acetone ≤ 5000 ppm; Methanol ≤ 3000 ppm | 1,2-Dichloroethane ≤ 5 ppm. (process-specific); Pyridine ≤ 200 ppm |
| Lincomycin B content (related compound) | ≤ 5.0% (EP impurity B) | Lincomycin HCl impurity in clindamycin: ≤ 1.0% |
| Bacterial endotoxins | ≤ 0.5 EU/mg (if parenteral grade) | ≤ 0.5 EU/mg (if parenteral grade) |
Process-scale crystallisation from acetone/water mixtures (4:1 v/v) at controlled cooling rates of 0.5°C/min yields the monohydrate with a D90 particle size typically between 45 µm and 150 µm, as measured by laser diffraction (Malvern Mastersizer 3000, dry dispersion at 2 bar). Milled lots destined for oral dry syrups are often jet-milled to D90 ≤ 25 µm; however, excessive micronisation pressure above 6 bar can generate amorphous domains that reduce the onset temperature of the first endothermic event in DSC (heating rate 10 K/min, crimped Al pan) from 145–150°C to below 130°C, correlating with a 0.8% increase in total related substances after 6 months at 40°C/75% RH.
Impurity Mapping Under ICH Q3A/Q3B Thresholds and Forced Degradation Studies
Regulatory submission batches require quantitative tracking of at least seven structurally assigned impurities. The most persistent process-related impurity is S-demethyl lincomycin (lincomycin B, EP Impurity B, CAS 16843-08-6), which co-elutes with the main peak on conventional C18 columns under the isocratic mobile phase conditions of USP Monograph for Lincomycin Hydrochloride. Resolution ≥ 1.5 between lincomycin and lincomycin B is achieved only when the column temperature is elevated to 55°C and the acetonitrile:phosphate buffer (pH 6.0; 0.05 M) ratio is adjusted to 22:78 v/v on a 4.6 × 150 mm, 5 µm octadecylsilane chemically bonded to 100 Å silica. Under these conditions, the relative retention time of lincomycin B is 1.3 with respect to the principal peak. An impurity profile obtained from a 12-month ICH stability study at 25°C/60% RH showed that the sum of unidentified impurities observed at RRT 0.87 and 1.62 remained below the 0.10% identification threshold, while total degradation products stayed below 0.5% through 24 months in aluminium foil blister packs.
Forced degradation under oxidative stress (hydrogen peroxide 3% v/v, 24 h at 25°C) preferentially attacks the thioether bridge, yielding the (R)-sulfoxide (EP Impurity D) at levels of 4–7% and the sulfone at 0.3–1.0%. Under alkaline hydrolysis (NaOH 0.1 M, 60°C for 2 h), cleavage of the amide bond releases the propylproline moiety, 1-methyl-4-propyl-L-proline, which can be detected at 210 nm with a limit of quantitation of 0.02%. The pharmacopoeial limit for any unspecified impurity is set at ≤ 0.10% per Ph. Eur. monograph 0583, mirroring ICH Q3B thresholds for a maximum daily dose exceeding 2 g. The monohydrate form exhibits a slightly elevated susceptibility to photolytic N-demethylation compared to the anhydrous form when exposed to 1.2 million lux·h of cool white fluorescent light per ICH Q1B Option 2, producing N-desmethyl lincomycin (EP Impurity C) at 0.18% versus 0.12% in the anhydrous material; therefore, primary packaging must incorporate a UV-absorbing PVC/PCTFE blister.
Microbiological Spectrum and the Risk of Resistance Selection in Veterinary Versus Human Isolates
Lincomycin binds the 50S ribosomal subunit at a domain V nucleotide pocket that overlaps the binding region of clindamycin and erythromycin, inhibiting peptide chain elongation. The minimum inhibitory concentration required to inhibit 90% of isolates (MIC90) for clinical Staphylococcus aureus (methicillin-susceptible) ranges from 0.5 µg/mL to 2 µg/mL when tested by broth microdilution per CLSI M07-A10. For Streptococcus pneumoniae, MIC90 values of 0.25–1 µg/mL are reported; however, macrolide-lincosamide-streptogramin B (MLSb) resistance mediated by erm genes confers cross-resistance with an MIC elevation to > 64 µg/mL. This cross-resistance severely restricts empirical monotherapy in regions where constitutive erm expression exceeds 15% among clinical isolates. The veterinary feed-grade product — often supplied as lincomycin hydrochloride soluble powder meeting VICH GL11 purity — is associated with a lower prevalence of plasmid-mediated lnu (lincosamide nucleotidyltransferase) resistance than the human therapeutic form, likely due to differences in dosing regimen and gut microbial ecology in swine and poultry.
When substituting lincomycin for clindamycin in penicillin-allergic patients, clinicians must note that lincomycin demonstrates 2- to 4-fold lower activity against Bacteroides fragilis group anaerobes, with typical MIC90 values of 4–16 µg/mL versus 0.5–2 µg/mL for clindamycin. This limitation arises directly from the absence of the 7(S)-chloro substituent, which reduces passive diffusion across the outer membrane of Gram-negative anaerobes. The phosphate salt for parenteral administration, not the hydrochloride, is chosen for intramuscular injection to avoid pain upon administration; the hydrochloride monohydrate remains the form of choice for oral capsules and syrups.
Conditioning, Sampling Plans, and Karl Fischer Method Parameters
A double-cone dryer operating at a jacket temperature of 40°C and vacuum of 10–20 mbar is employed to adjust the water content of the final crystallized monohydrate to 4.7–5.3%. In-process control relies on at-line near-infrared spectroscopy (Büchi NIRMasterTM) calibrated against volumetric Karl Fischer titration using HydranalTM-Composite 5 as the working medium. The sampling plan follows ISO 2859-1, with an AQL of 0.65% for water content and 0.25% for assay. Karl Fischer oven-sample changer parameters are set to 160°C for 12 min to liberate lattice water without evolving volatile degradation products that would bias the coulometric endpoint; below 150°C, insufficient dehydration of the crystal yields water results 0.3–0.5% lower than the true stoichiometric monohydrate value, as verified by thermogravimetric analysis at 5 K/min.
Given the hygroscopic nature of the amorphous fraction generated by milling, a reconditioning step at 50% RH and 20°C for 48 h is frequently necessary before bulk packaging into double polyethylene liners inside fibre drums. Without reconditioning, electrostatic charging during transfer into capsule-filling hoppers (Zanasi 40E) leads to powder adhesion and segmented weight drift exceeding 7.5% RSD within 15 min of operation.
| Solvent | Class (ICH Q3C) | PDE (mg/day) | Concentration Limit (ppm) | Typical Control Result (GC-FID Headspace) |
|---|---|---|---|---|
| Acetone | 3 | 50 | 5000 | 320–450 ppm |
| Methanol | 2 | 30 | 3000 | 45–90 ppm |
| Isopropyl alcohol | 3 | 50 | 5000 | < 10 ppm |
| Ethyl acetate | 3 | 50 | 5000 | < 25 ppm |
The monohydrate hydrochloride salt is incompatible with strong oxidizing agents and alkalizing media at concentrations sufficient to raise the solution pH above 6.5, at which point the solubility of the free base decreases to less than 2 mg/mL at 20°C, risking precipitation in intravenous admixtures. In solid dosage forms, pre-formulation compatibility screening using binary mixtures stored at 40°C/75% RH for 4 weeks has demonstrated a 0.35% increase in total impurities when blended with magnesium stearate at 1.0% w/w, relative to 0.08% increase with sodium stearyl fumarate, indicating a slight sensitivity to alkaline lubricants. No significant Maillard reaction products are observed with lactose monohydrate under the same conditions, confirming the absence of reactive primary amine groups in the lincomycin molecule beyond the amino acid originated pyrrolidine nitrogen, which remains protonated in the salt form.
Quality Control Release Testing in a GMP Environment
Lot release testing for lincomycin hydrochloride monohydrate intended for the European market requires a certificate of analysis that explicitly addresses monohydrate identification by X-ray powder diffraction (XRPD) per Ph. Eur. 2.9.33. Characteristic peaks at 8.7° 2θ, 14.2° 2θ, and 22.1° 2θ (Cu Kα radiation, 40 kV, 40 mA) differentiate the monohydrate from the anhydrous form, which exhibits a singlet at 9.2° 2θ and a doublet at 14.8° and 15.1° 2θ. Microbial enumeration tests follow Ph. Eur. 2.6.12 and 2.6.13, with acceptance criterion TAMC ≤ 10³ CFU/g and TYMC ≤ 10² CFU/g. Absence of Escherichia coli is demonstrated in 10 g of product. For veterinary premix grades, heavy metals are controlled at ≤ 10 ppm for lead, ≤ 0.1 ppm for mercury, and ≤ 1 ppm for cadmium by ICP-MS per USP 〈233〉.
The HPLC system suitability test for assay uses a solution of lincomycin hydrochloride standard containing 0.25 mg/mL; the relative standard deviation of the peak area for five replicate injections must not exceed 2.0%, and the tailing factor for the lincomycin peak is ≤ 2.0 at 10% peak height. Columns packed with end-capped octadecylsilane (USP L1, 4.6 × 250 mm, 5 µm) are suitable; however, brand-to-brand selectivity variations regarding the separation of lincomycin B warrant a system suitability mixture containing 0.1% of the related compound. Published retention times for the principal peak typically range from 8.5 to 10.2 min under the official monographic conditions at 1.0 mL/min.
